Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer: an Open Label, Phase II Trial

NCT05004974 is registered in ClinicalTrials.gov with The Fourth Affiliated Hospital of Zhejiang University School of Medicine as lead sponsor.

NCT NCT05004974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05004974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer: an Open Label, Phase II Trial
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 2
Overall status
Unknown status
Start date
April 26, 2022
Completion date
September 30, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer